April 2018 Newsletter

Themes from April

Sainsbury/ ASDA agreed a merger which will see US Walmart hold 42% of the enlarged group.

April 2018 saw a sharp rebound in UK blue chips which added c. 450 points due to M&A activity, higher commodity prices and declining UK gilt yields.

Glencore had a busy month with CEO Ivan Glasenberg resigning from Rusal following the US move to impose sanctions. Glencore was then sued for $2.95bn by Dan Gertler and freezing orders have been put in place on two of its DRC copper mines.

Takeda Pharmaceuticals fifth proposal to acquire Shire Pharmaceuticals got a tentative nod from the Shire board. The terms are 0.839x Takeda and $30.33 in cash per Shire share.

President Macron admitted that his visit to Washington to persuade US President Donald Trump to keep to the Iran nuclear deal “probably failed”.

Hammerson rejected a revised takeover proposal from Klepierre at 635p per share but facing increasing shareholder opposition then changed its mind on the merger with rival Intu Properties.

Barclays reported Q1 loss of £236m with TNAV declining to 251p from 276p. CEO Jes Staley promised to increase shareholder returns via a share buyback, but did not provide further details.

Forthcoming UK Events

1 May Markit/ CIPS Manufacturing PMI/ BoE Consumer Credit
2 May Construction PMI
3 May Local Government Elections / 5 YR Treasury Auction
4 May New Car Sales
8 May Halifax House Price Index
10 May UK Balance of Trade/ UK Industrial Production/ UK Manufacturing Production/ MPC meeting
15 May UK Unemployment Rate/ Average Earnings/ Claimant Count Change
16 May Labour Productivity QTR
21 May CBI Industrial Trends
22 May Public Sector Net Borrowing
23 May PPI Output/ Retail Price Index/ Inflation Rate

Performance of World Markets (30/4/2018)

North America Value Change +/-(1M)% +/-(1YR)%
DOW JONES (Close) 24,163.15 60.15 0.25 15.53
S&P 500 (Close) 2,648.05 7.18 0.27 10.87
NASDAQ (Close) 7066.27 2.83 0.04 16.00
Europe/UK Value Change +/-(1M)% +/-(1YR)%
UK 100 INDEX (Close) 7,509.30 452.69 6.41 3.57
CAC 40 INDEX (Close) 5,520.50 353.20 6.83 4.07
EUROSTOXX 50 (Close) 3,534.19 172.69 5.13 -1.23
Asia/Far East Value Change +/-(1M)% +/-(1YR)%
SHANGHAI COMPOSITE (Close) 3,082.23 -86.67 -2.81 -1.95
NIKKEI-225 (Close) 22,467.87 1,013.57 4.72 15.54
ASX 200 (Close) 5,982.70 229.10 3.82 0.54
HANG SENG (Close) 30,808.45 785.92 2.61 24.75

United Kingdom

UK blue chips bounced 452 points during April on the back of higher commodities, lower sterling and expectations that the Bank of England is dialing back on its rate rise agenda. Speaking at the IMF meeting in Washington Governor Mark Carney suggested that the MPC could wait longer.

Saudi Arabia’s apparent intention to keep crude oil above $70/ barrel, the prospect of new sanctions on Iran which could remove 800k barrels of Iranian crude from the global market and strong global GDP growth have kept Brent underpinned, boosting UK oil majors and oil services.

M&A is a major feature in 2018 with deals being rushed through whilst sterling remains cheap. But not all M&A gets to the finish line, if anything it has become harder to complete. And it is taking longer these days to get completion.

Target Acquirer No of attempts Comment
Smurfitt Kappa Intl Paper 3 Smurfitt are wanting an unrealistic price
Shire Ph. Takeda 5 Shire wants alternative buyer
ASDA Sainsbury 1 Regulatory complications
Sky Comcast 2 Ball is now in Fox / Disney court


Tokyo investors are concerned about Takeda Pharmaceuticals whose new CEO, Frenchman Christophe Weber is hell bent on acquiring Shire Pharmaceuticals following on from recent bolt on acquisitions. The Shire merger, if completed, will see Takeda shouldering a debt of c. US$40bn has caused a significant sell off in Takeda’s shares.

Takeda Pharmaceuticals

Source: www.google.com

Takeda is taking significant risks, especially if the Trump Administration pursues pharmaceutical price cuts, which would hit the pricing of Shire’s expensive rare drugs.
The proposed merger has left many analysts scratching their heads as to its merits, as there do not appear to be significant synergies or overlap. Weber still has to get his shareholders onboard, and arrange financing. The whole process has shown Takeda is desperate to buy Shire.


French tycoon, Vincent Bollore has hit back against allegations that he undercharged the presidents of Guinea and Togo for advertising on their election campaigns as an incentive to award Bollore Group port concessions. Bollore claimed that the claims were rooted in prejudice against African leaders.

Bollore SA shares dropped from highs of €4.50 on April 19th 2018 to €4.12 on concern that the corruption probe might uncover wrongdoing in its lucrative port and oil storage operations in west Africa. There may also be executive changes. The Euro declined noticeably vs. the USD over April reversing from highs of $1.24 to just above $1.20.


United States

The US Q1 season started with high expectations, consensus for the S&P 500 was a 24.6% rise in earnings, according to Reuters. Excluding the energy sector the Q1 earnings growth estimate was around 22.8%. These were very high forecasts.

Of the 274 / 500 US companies that have so far reported, 79.2% have reported earnings above estimates (above the long term average of 64%) whilst average revenue growth has been 8.1%.

Q1 earnings growth has been helped by cuts in corporation tax but this is part of the 2018 story. Robust global growth is also important.

The US market is skewed with the top ten technology companies expected to reach $1trn in revenues in 2018. Recent moves in the “market cap wars” has seen movie streaming giant Netflix (NASDAQ: NFLX) market cap reach $136.5bn just above IBM (NYSE: IBM) at $133.75bn. Facebook market cap at $500bn exceeds both Exxon Mobil ($342bn) and Walt Disney ($152bn). Sign of the times?

Philip Morris fell after Q1 tobacco shipments declined 5.3% meaning revenues were $103m behind forecasts of $7.03bn. Smokers have proved slow to move to “next generation” vaping and heated tobacco products.

Subscribe to our Award-winning Newsletter

We provide daily market data in the form of our award-winning newsletter, The Morning Call and The Market Close.
You can subscribe to this information at any time to help you make the most of your investment.

Quick Sign-up

Important Information

Key to Material Interests:

Please be aware that the following disclosures of Material Interests are relevant to this research note:

Shire Pharma                        Relevant disclosures:   <2>

Hammerson                           Relevant disclosures:   <2>

Takeda Pharma                    Relevant disclosures:   <2>

Bollore SA                              Relevant disclosures:   <2>

J Sainsbury                            Relevant disclosures:   <2>

Glencore                                 Relevant disclosures:   <2>

IBM                                           Relevant disclosures:   <2>

Walt Disney                           Relevant disclosures:   <2>

Facebook                                Relevant disclosures:   <2>

Philip Morris Int                 Relevant disclosures:   <NA>

Smurfitt Kappa                    Relevant disclosures:   <2>

Comcast                                  Relevant disclosures:  <NA>

Sky                                            Relevant disclosures:  <2>

Barclays                                  Relevant disclosures:  <2>

  1. The analyst has a personal holding in the securities issued by the company or of derivatives linked to the price of the company’s securities.
  2. Collins Sarri Statham Investments Ltd has clients who hold either shares or CFD positions in this security.

Analyst Certification:

The report’s author certifies that this research report accurately states his personal views about the subject securities, which is reflected in the ratings as well as the substance of the reports.


Collins Sarri Statham Investments Ltd (CSS) does not in any of its publications take into account any particular recipient's investment objectives, financial situation, and specific needs and demands. Therefore, all CSS publications are, unless otherwise specifically stated, intended for informational and/or marketing purposes only.CSS shall not be responsible for any loss arising from any investment based on a perceived recommendation.

No publication (including recommendations) shall be construed as a representation or warranty that the recipient will profit, nor avoid sustaining losses, from trading in accordance with a trading strategy set forth in a publication.

This research is non-independent and is classified as a Marketing Communication under FCA rules detailed in their Conduct of Business Rulebook (COBS). As such it has not been prepared in accordance with legal requirements designed to promote independence of investment research and it is not subject to the prohibition of dealing ahead of the dissemination of investment research outlined in COBS 12.2.18.

Risk Warning:

Trading in the products and services offered by Collins Sarri Statham Investments Ltd (CSS) may, result in losses as well as profits as the value of investments may go down as well as up. You may not get back the full amount you have invested. Any reference to past performance should not be viewed as an indication of any future performance. Investments held in overseas markets are subject to the effects of changes in exchange rates which will impact on the value of the underlying investment. Investments made in AIM and penny shares carry an increased risk due to the difficulty in creating a market in these shares. There may be a substantial difference in the buy and sell price. Leveraged products such as Contracts for Difference (CFDs), derivatives, commodities & Foreign Exchange (FX), carry a higher risk to your capital. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 72% of retail investor accounts lose money when trading CFDs with this provider (Saxo Bank). You should consider whether you understand how CFDs, FX or any of our other products work and whether you can afford to take the high risk of losing your money. Losses can exceed deposits on some products.

Speculative Trading is not Suitable for all Investors

The information contained herein is based on materials and sources that we believe to be reliable however we make no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Please note that the figures shown may, in some instances, be rounded to the nearest penny. Prices can move sharply from those quoted in this document. Current prices can be verified by calling one of our brokers. CSS is under no obligation to update the information contained herein. Neither CSS, nor its affiliates, nor its employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from the use of this document.

Get Started with CSS

Open an Account

Subscribe to our award winning daily newsletter

Voted "Best Market Newsletter" in 2012, 2014, 2015 and 2017 by the City of London Wealth Management Awards

Subscribe to our newsletter (Popup)

By signing up to our free email, you are consenting to receive these promotions. The newsletter is sent up to three time per day during the week and up to once per day over the weekend. The newsletter contains company news, market movements, CSS research and promotions and breaking economic news. Occasionally our newsletter will contain advertisements from trusted partners. However, we will never give, sell or rent your email address to any other companies. If you want to stop receiving our free emails you can unsubscribe at any time by clicking on the link at the bottom of each email. You can read our privacy policy here.

No, thank you